Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LaserSight's LaserScan LSX Will Be Sold By Six U.S. Direct Sales Reps

This article was originally published in The Gray Sheet

Executive Summary

LaserSight will seek approval of its LaserScan LSX laser assisted in situ keratomileusis (LASIK) system for correction of farsightedness (hyperopia).

You may also be interested in...

LaserSight Excimer Laser Sales On Hold Pending Visx License Negotiations

LaserSight says it will delay marketing of the LaserScan LSX ophthalmic excimer laser system in the U.S. while it negotiates a license agreement with competitor Visx.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts